RPRX β€” ROYALTY PHARMA PLC

Ownership history in PDT Partners, LLC  Β·  10 quarters on record

This page tracks every 13F SEC filing in which PDT Partners, LLC reported a position in ROYALTY PHARMA PLC (RPRX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
0.38% (2023 Q4)
πŸ“Š Avg. % of fund
0.18%
πŸ“… First filed
2023 Q1
πŸ“… Last filed
2025 Q3
⏱ Quarters held
10

Position Intelligence

PDT Partners, LLC Γ— RPRX AI Analytics

πŸ“‰ PDT Partners, LLC underperformed the S&P 500 by –19.6% annually on this RPRX position. Timing score: 67% (6/9 decisions correct). Average cost basis: $27.29. Maximum drawdown during holding period: –25.5%.

πŸ“ˆ Position Alpha vs SPY
-19.6%
annualised excess return

❌ Significantly underperformed the S&P 500 by 19.6% ann.
9 quarters analyzed

⏱️ Timing Score
67%

βœ… Decent timing β€” more right than wrong on entries and exits.
6 of 9 add/trim decisions correct

πŸ’° Entry Quality
$27.29
+27.9% vs current ($34.90)

Best entry: $24.75 (2024 Q4)  Β·  Worst: $33.23 (2023 Q1)

πŸ›‘οΈ Drawdown Resilience
–25.5%
max drawdown while held

πŸ’ͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.

πŸ’ͺ Fund Conviction
50%
buy-side decisions

5 adds Β· 5 trims. Bought during 2 of 5 down-price quarters. πŸ“ˆ More buys than sells across the holding period.

πŸ“‘ Position Trajectory
β†’ Stable
last 4–5 quarters trend

βš–οΈ Portfolio weight has remained relatively stable β€” conviction maintained.
Currently 0.06% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    RPRX price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 10 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 27,840 -41,693 -60.0% 0.06% $982K $34.90
2025 Q2 REDUCED 69,533 -100 -0.1% 0.14% $2.5M $35.43
2025 Q1 ADDED 69,633 +100 +0.1% 0.15% $2.2M $30.41
2024 Q4 ADDED 69,533 +38,599 +124.8% 0.16% $1.8M $24.75
2024 Q3 REDUCED 30,934 -20,502 -39.9% 0.08% $875K $27.23
2024 Q2 REDUCED 51,436 -69,623 -57.5% 0.13% $1.4M $25.18
2023 Q4 ADDED 121,059 +12,600 +11.6% 0.38% $3.4M $26.44
2023 Q3 ADDED 108,459 +74,037 +215.1% 0.37% $2.9M $25.35
2023 Q2 REDUCED 34,422 -7,978 -18.8% 0.15% $1.1M $28.52
2023 Q1 INITIATED 42,400 β€” β€” 0.21% $1.5M $33.23

🏒 Other funds also holding RPRX

As of 2025 Q4 β€” sorted by position size

Dorsey Asset Management, LLC 3Y 7Y 7.59% Regal Partners Ltd 3Y 7Y 5.88% Caledonia (Private) Investments Pty Ltd 3Y 7Y 5.46% NEW SOUTH CAPITAL MANAGEMENT INC 3Y 7Y 5.21% Patient Capital Management, LLC 3Y 4.97% Lion Point Capital, LP 3Y 7Y 4.28% TORRAY INVESTMENT PARTNERS LLC 3Y 7Y 4.12% Goodman Advisory Group, LLC 3Y 2.67% CM Management, LLC 3Y 2.44% Inlet Private Wealth, LLC 3Y 7Y 2.02%
← Back to PDT Partners, LLC Holdings